Astellas Partners with the Quebec Urological Association Foundation to Advance Urology Research

MARKHAM, ON, Nov. 10, 2016 /CNW/ - Astellas Pharma Canada, Inc. (Astellas) today announced a new research collaboration with the Quebec Urological Association Foundation (QUAF) to provide funding and support for urology research in the province of Quebec.

The QUAF Astellas Research Grant Program will award a total of up to $150,000 over three years to support Canadian investigators in the field of urology. The primary objective of this new grant program is to advance peer-reviewed research in functional urology, with the ultimate goal of improving patient care.

The support of this new grant reflects an ongoing commitment by Astellas to the Canadian urologic community and provides a distinct program specifically geared towards researchers in the functional urology area who are based in Quebec.

"Astellas is proud to partner with the Quebec Urological Association Foundation to support the work of investigators and clinical trainees based in Quebec. It is our hope that this new grant program will create opportunities to advance research that can make a significant difference in patients' lives," said Fran Paradiso-Hardy, Senior Director, Medical Affairs at Astellas Pharma Canada.

"It is always a pleasure to work in close collaboration with our partners at Astellas, who continue to demonstrate their commitment to the Quebec urologic community. This partnership will ultimately lead to advancements in the field of urology and to cutting edge patient care," said Dr. Marie-Paule Jammal, President, Quebec Urology Association Foundation.

The call for submissions for the 2016 QUAF Astellas Research Grant will open January 6, 2017 and close March 1, 2017.  Recipients will be notified June 2017.

For more information about the application process and eligibility criteria, please visit the Association des urologues du Québec (AUQ) website, www.auq.org

About the Quebec Urological Association Foundation (QUAF)
The Quebec Urological Association Foundation (QUAF) is headquartered in Montreal, QC and received full accreditation as non-profit organization in 2000.  Its mission is to promote the quality of Urology in Quebec by giving scholarships for post-graduate studies, and grants to stimulate clinical and fundamental research. More information about the QUA/AUQ can found at www.auq.org

About Astellas Pharma Inc.
Astellas Pharma Inc., based in Tokyo, Japan, is a company dedicated to improving the health of people around the world through the provision of innovative and reliable pharmaceutical products. We focus on Urology, Oncology, Immunology, Nephrology and Neuroscience as its prioritized therapeutic areas while advancing new therapeutic areas and discovery research leveraging new technologies/modalities. We are also exploring to create new values by combining internal capabilities and external expertise in medical/healthcare business. Astellas stays on the forefront of healthcare change and turn innovative science into values for patients. For more information, please visit our website at www.astellas.com/en.

About Astellas Pharma Canada, Inc.
Astellas Pharma Canada, Inc., headquartered in Markham, ON, is a Canadian affiliate of Tokyo-based Astellas Pharma Inc. In Canada, Astellas has an intense commercial focus on four therapeutic areas – Urology, Immunology, Infectious Disease and Oncology.

For more information about Astellas Pharma Canada, Inc., please visit the corporate website:  www.astellas.ca

SOURCE Astellas Pharma Canada, Inc.

Ms. Liliane Verret, Quebec Urological Association, 2 Complexe Desjardins Tour de l'est (32e étage), Montréal QC H5B 1G8, Phone : [phone], Fax : [phone], Email: [email protected]; Michelle Reale, Corporate Communications, Astellas Pharma Canada, Inc., 905-946-5621, [email protected]